Alemtuzumab based reduced intensity conditioning allogeneic haematopoietic stem cell transplantation for myelofibrosis

W. Nagi; Z. Y. Lim; P. Krishnamurthy; Victoria Potter; V. Tindell; L. Reiff-Zall; A. Abdullah; N. Lea; M. Kenyon; J. Marsh; A. Y. L. Ho; G. J. Mufti; Tony Pagliuca

doi:10.1016/j.leukres.2011.02.012

Alemtuzumab based reduced intensity conditioning allogeneic haematopoietic stem cell transplantation for myelofibrosis

W. Nagi, Z. Y. Lim, P. Krishnamurthy, Victoria Potter, V. Tindell, L. Reiff-Zall, A. Abdullah, N. Lea, M. Kenyon, J. Marsh, A. Y. L. Ho, G. J. Mufti, Tony Pagliuca

King's College London

Research output: Contribution to journal › Article › peer-review

2 Citations (Scopus)

Abstract

We report the results of 11 patients myelofibrosis, who have received a uniform alemtuzumab-based RIC HSCT. The median recipient age was 51 years. Stem cells were obtained from 8 full HLA-matched and 3 HLA-mismatched donors. The 2-year OS and TRM at 2-years was 46% and 54% with no disease relapse observed. For patients with a full HLA-matched donor, the 2-year TRM and OS was 37.5% and 62.5%. All 4 JAK2 V617F mutant positive patients achieved molecular remission after a median of 90 days post-transplant, and the median time to regression of bone marrow fibrosis was 180 days.

Original language	English
Pages (from-to)	998 - 1000
Number of pages	3
Journal	Leukemia Research
Volume	35
Issue number	8
DOIs	https://doi.org/10.1016/j.leukres.2011.02.012
Publication status	Published - Aug 2011

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.leukres.2011.02.012

Cite this

Nagi, W., Lim, Z. Y., Krishnamurthy, P., Potter, V., Tindell, V., Reiff-Zall, L., Abdullah, A., Lea, N., Kenyon, M., Marsh, J., Ho, A. Y. L., Mufti, G. J., & Pagliuca, T. (2011). Alemtuzumab based reduced intensity conditioning allogeneic haematopoietic stem cell transplantation for myelofibrosis. Leukemia Research, 35(8), 998 - 1000. https://doi.org/10.1016/j.leukres.2011.02.012

@article{c8fb149cc3f44b898a7a33b74c4a88e3,

title = "Alemtuzumab based reduced intensity conditioning allogeneic haematopoietic stem cell transplantation for myelofibrosis",

abstract = "We report the results of 11 patients myelofibrosis, who have received a uniform alemtuzumab-based RIC HSCT. The median recipient age was 51 years. Stem cells were obtained from 8 full HLA-matched and 3 HLA-mismatched donors. The 2-year OS and TRM at 2-years was 46% and 54% with no disease relapse observed. For patients with a full HLA-matched donor, the 2-year TRM and OS was 37.5% and 62.5%. All 4 JAK2 V617F mutant positive patients achieved molecular remission after a median of 90 days post-transplant, and the median time to regression of bone marrow fibrosis was 180 days.",

author = "W. Nagi and Lim, {Z. Y.} and P. Krishnamurthy and Victoria Potter and V. Tindell and L. Reiff-Zall and A. Abdullah and N. Lea and M. Kenyon and J. Marsh and Ho, {A. Y. L.} and Mufti, {G. J.} and Tony Pagliuca",

year = "2011",

month = aug,

doi = "10.1016/j.leukres.2011.02.012",

language = "English",

volume = "35",

pages = "998 -- 1000",

journal = "Leukemia Research",

publisher = "Elsevier Limited",

number = "8",

}

Nagi, W, Lim, ZY , Krishnamurthy, P , Potter, V, Tindell, V, Reiff-Zall, L, Abdullah, A, Lea, N , Kenyon, M , Marsh, J , Ho, AYL , Mufti, GJ & Pagliuca, T 2011, 'Alemtuzumab based reduced intensity conditioning allogeneic haematopoietic stem cell transplantation for myelofibrosis', Leukemia Research, vol. 35, no. 8, pp. 998 - 1000. https://doi.org/10.1016/j.leukres.2011.02.012

TY - JOUR

T1 - Alemtuzumab based reduced intensity conditioning allogeneic haematopoietic stem cell transplantation for myelofibrosis

AU - Nagi, W.

AU - Lim, Z. Y.

AU - Krishnamurthy, P.

AU - Potter, Victoria

AU - Tindell, V.

AU - Reiff-Zall, L.

AU - Abdullah, A.

AU - Lea, N.

AU - Kenyon, M.

AU - Marsh, J.

AU - Ho, A. Y. L.

AU - Mufti, G. J.

AU - Pagliuca, Tony

PY - 2011/8

Y1 - 2011/8

N2 - We report the results of 11 patients myelofibrosis, who have received a uniform alemtuzumab-based RIC HSCT. The median recipient age was 51 years. Stem cells were obtained from 8 full HLA-matched and 3 HLA-mismatched donors. The 2-year OS and TRM at 2-years was 46% and 54% with no disease relapse observed. For patients with a full HLA-matched donor, the 2-year TRM and OS was 37.5% and 62.5%. All 4 JAK2 V617F mutant positive patients achieved molecular remission after a median of 90 days post-transplant, and the median time to regression of bone marrow fibrosis was 180 days.

AB - We report the results of 11 patients myelofibrosis, who have received a uniform alemtuzumab-based RIC HSCT. The median recipient age was 51 years. Stem cells were obtained from 8 full HLA-matched and 3 HLA-mismatched donors. The 2-year OS and TRM at 2-years was 46% and 54% with no disease relapse observed. For patients with a full HLA-matched donor, the 2-year TRM and OS was 37.5% and 62.5%. All 4 JAK2 V617F mutant positive patients achieved molecular remission after a median of 90 days post-transplant, and the median time to regression of bone marrow fibrosis was 180 days.

U2 - 10.1016/j.leukres.2011.02.012

DO - 10.1016/j.leukres.2011.02.012

M3 - Article

VL - 35

SP - 998

EP - 1000

JO - Leukemia Research

JF - Leukemia Research

IS - 8

ER -

Alemtuzumab based reduced intensity conditioning allogeneic haematopoietic stem cell transplantation for myelofibrosis

Abstract

UN SDGs

Access to Document

Fingerprint

Cite this